Arovella Boosts Cash Reserves with Additional R&D Tax Rebate

Arovella Therapeutics Limited ( (AU:ALA) ) has shared an announcement.

Arovella Therapeutics has received an additional A$0.28 million under Australia’s R&D Tax Incentive, linked to eligible overseas research expenditure for FY2025 that was recognised after its original tax return, which had already generated a A$3.2 million refund. The extra rebate bolsters the company’s cash reserves as it advances its lead iNKT cell therapy candidate, ALA-101, toward first-in-human clinical trials, underscoring ongoing government support for its oncology-focused research pipeline.

Management highlighted the importance of the R&D Tax Incentive in funding early-stage biotech development, with the latest payment expected to help sustain progress across Arovella’s cell therapy programs. The funding support may strengthen Arovella’s financial runway and operational flexibility in a highly capital-intensive sector, potentially improving its competitive positioning in next-generation cancer cell therapies.

More about Arovella Therapeutics Limited

Arovella Therapeutics Ltd is an Australian biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19 and CD1d, and the company is also advancing CLDN18.2- and IL-12-TM-based technologies for solid tumour indications.

Average Trading Volume: 1,049,183

Technical Sentiment Signal: Sell

Current Market Cap: A$112.4M

See more data about ALA stock on TipRanks’ Stock Analysis page.